Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance HealthASX:RHT +7.69% Return-on-Tangible-Asset is 34.66% as of Dec. 2025. The stock has 8 warning signs investors should review. Among 680 Healthcare Providers & Services companies, Resonance Health ranks better than 78.09% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Resonance Health's annualizedNet Income for the quarter that ended in Dec. 2025 was A$2.93 Mil. Resonance Health's average total tangible assets for the quarter that ended in Dec. 2025 was A$8.46 Mil. Therefore, Resonance Health's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 34.66%.
The historical rank and industry rank for Resonance Health's Return-on-Tangible-Asset or its related term are showing as below:
ASX:RHT'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -15.6 Med: -9.35 Max: 36.14
Current: 9.17
During the past 13 years, Resonance Health's highest Return-on-Tangible-Asset was 36.14%. The lowest was -15.60%. And the median was -9.35%.
ASX:RHT's Return-on-Tangible-Asset is ranked better than 78.09% of 680
companies
in the Healthcare Providers & Services industry
Industry Median: 2.465
vs ASX:RHT: 9.17
Resonance Health (ASX:RHT) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Resonance Health Return-on-Tangible-Asset Related Terms
Resonance Health Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Resonance Health's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHT vs VEEV, BTSG, HQY: Return-on-Tangible-Asset Comparison
For the Health Information Services subindustry, Resonance Health's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Resonance Health's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 34.66% mean?
Resonance Health (ASX:RHT) has a Return-on-Tangible-Asset of 34.66% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Resonance Health and its competitors. According to the industry distribution chart, Resonance Health ranks #149 out of 680 companies in the Healthcare Providers & Services industry, placing it in the top 21.9%.
Is Resonance Health's Return-on-Tangible-Asset too high?
Resonance Health's current Return-on-Tangible-Asset is 34.66%. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.47. Resonance Health's value of 34.66% is 1306.1% above this industry median. Based on the distribution chart, Resonance Health ranks #149 out of 680 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Resonance Health's Return-on-Tangible-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #149 out of 680 companies for Return-on-Tangible-Asset. This places Resonance Health in the top 22% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.47. Resonance Health's value of 34.66% is 1306.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.47, based on 680 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current Return-on-Tangible-Asset of 34.66% is 1306.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current Return-on-Tangible-Asset is 34.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.06 — trading 53.3% below its estimated fair value. The current Return-on-Tangible-Asset is 34.66% and 1306.1% above the Healthcare Providers & Services industry median of 2.47. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Return-on-Tangible-Asset is 34.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 
